Quick Answer
Lexeo Therapeutics, Inc. reported Cash and Equivalents of $63.00 million for fiscal year 2025.
Lexeo Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $63.00M | +79.9% |
| 2024 | $35.01M | -71.2% |
| 2023 | $121.47M | +57.1% |
| 2022 | $77.33M | -43.1% |
| 2021 | $135.86M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $41.00M | -73.9% | +15.5% |
| June 30, 2025 | $35.48M | -79.7% | +22.7% |
| March 31, 2025 | $28.91M | -85.2% | -17.4% |
| December 31, 2024 | $35.01M | -71.2% | -77.7% |
| September 30, 2024 | $157.02M | +342.9% | -10.3% |
| June 30, 2024 | $174.98M | — | -10.3% |
| March 31, 2024 | $195.06M | — | +60.6% |
| December 31, 2023 | $121.47M | +57.1% | +242.7% |
- Lexeo Therapeutics, Inc. showed an increase of +79.9% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2021–2025 period, Lexeo Therapeutics, Inc.’s cash and equivalents has declined by 53.6% (from $135.86 million to $63.00 million).
- The most recent figure is from Lexeo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: